ALLOGENE THERAPEUTICS INC's ticker is ALLO and the CUSIP is 019770106. A total of 170 filers reported holding ALLOGENE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 1.82 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $296,433 | -35.4% | 93,512 | +1.3% | 0.00% | – |
| Q2 2023 | $458,582 | -2.3% | 92,270 | -2.9% | 0.00% | – |
| Q1 2023 | $469,340 | -16.9% | 95,008 | +5.8% | 0.00% | – |
| Q4 2022 | $564,887 | -42.0% | 89,807 | -0.4% | 0.00% | – |
| Q3 2022 | $974,000 | -85.7% | 90,191 | -84.9% | 0.00% | -100.0% |
| Q2 2022 | $6,820,000 | +808.1% | 598,165 | +624.6% | 0.00% | – |
| Q1 2022 | $751,000 | +35.1% | 82,553 | +121.9% | 0.00% | – |
| Q4 2021 | $556,000 | -38.4% | 37,201 | +6.0% | 0.00% | – |
| Q3 2021 | $902,000 | -12.3% | 35,110 | -10.9% | 0.00% | – |
| Q2 2021 | $1,028,000 | +37.6% | 39,411 | +86.1% | 0.00% | – |
| Q1 2021 | $747,000 | +45.6% | 21,175 | +4.2% | 0.00% | – |
| Q4 2020 | $513,000 | +9.6% | 20,327 | +63.5% | 0.00% | – |
| Q3 2020 | $468,000 | -13.2% | 12,431 | -1.4% | 0.00% | – |
| Q2 2020 | $539,000 | +101.9% | 12,607 | -8.2% | 0.00% | – |
| Q1 2020 | $267,000 | – | 13,730 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 1,798,163 | $5,700,177 | 8.82% |
| Wildcat Capital Management, LLC | 1,920,787 | $6,088,895 | 2.44% |
| TPG GP A, LLC | 18,716,306 | $59,330,690 | 1.02% |
| EcoR1 Capital, LLC | 4,488,200 | $14,227,594 | 0.48% |
| CROSSPOINT FINANCIAL, LLC | 12,000 | $38,040 | 0.40% |
| Coastal Bridge Advisors, LLC | 406,847 | $1,289,705 | 0.35% |
| CAXTON ASSOCIATES LP | 480,104 | $1,521,930 | 0.21% |
| Woodline Partners LP | 5,313,915 | $16,845,111 | 0.20% |
| Rhenman & Partners Asset Management AB | 300,000 | $951,000 | 0.10% |
| Navalign, LLC | 75,365 | $238,907 | 0.09% |